Back to results
US 11,447,571 B2Granted
Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders
AssigneeHaemaLogix Pty Ltd
InventorRosanne Dunn
Life of this patent
Estimating the term…
Abstract
The present application is directed to anti-lambda myeloma antigen (LMA) binding proteins, wherein the binding protein is an antibody. Compositions comprising these antibodies and nucleic acids encoding these antibodies are also disclosed. These antibodies, compositions and nucleic acids may be used in the treatment of LMA expressing pathologies.
Claims6
An anti-LMA binding protein having an antigen binding domain that binds to LMA, the binding protein comprising:
- a VH comprising a CDR1 as shown in SEQ ID NO:
- 31, a CDR2 as shown in SEQ ID NO:
- 32, and a CDR3 as shown in SEQ ID NO:
- 33 and
- a first VL comprising a CDR1 as shown in SEQ ID NO:
- 36, a CDR2 as shown in SEQ ID NO:
- 37, and a CDR3 as shown in SEQ ID NO:
- 38;
- or
- a second VL comprising a CDR1 as shown in SEQ ID NO:
- 41, a CDR2 as shown in SEQ ID NO:
- 42 and a CDR3 as shown in SEQ ID NO:
- 43.
10 more elements
An anti-LMA binding protein having an antigen binding domain that binds to LMA, the binding protein comprising:
- a VH comprising a CDR1 as shown in SEQ ID NO:
- 61, a CDR2 as shown in SEQ ID NO:
- 62, and a CDR3 as shown in SEQ ID NO:
- 63 and
- a first VL comprising a CDR1 as shown in SEQ ID NO:
- 66, a CDR2 as shown in SEQ ID NO:
- 67, and a CDR3 as shown in SEQ ID NO:
- 68;
- or
- a second VL comprising a CDR1 as shown in SEQ ID NO:
- 71, a CDR2 as shown in SEQ ID NO:
- 72, and a CDR3 as shown in SEQ ID NO:
- 73.
10 more elements
Dependencies are inferred from the claim text.